JP7801491B2 - Vegf-aおよびil6に結合する抗体ならびに使用方法 - Google Patents

Vegf-aおよびil6に結合する抗体ならびに使用方法

Info

Publication number
JP7801491B2
JP7801491B2 JP2024566272A JP2024566272A JP7801491B2 JP 7801491 B2 JP7801491 B2 JP 7801491B2 JP 2024566272 A JP2024566272 A JP 2024566272A JP 2024566272 A JP2024566272 A JP 2024566272A JP 7801491 B2 JP7801491 B2 JP 7801491B2
Authority
JP
Japan
Prior art keywords
antibody
human
vegf
amino acid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024566272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025521085A5 (cg-RX-API-DMAC10.html
JP2025521085A (ja
Inventor
ベックマン,ローラント
ベンツ,イェルク
ベルトルド,ダヴィデ
ドラウネル,ファイ・マリー
フィーンストラ,デリック
フェン,セバスティアン
フロスト,シュテファン
ヒンナー,マーロン
イェンセン,クリスチャン・ホボルト
マッチェコ,ダニエラ
マイアー,アナスタシア
プローテナ,オリヴァー
ウィドマー,ガブリエラ
シュペック,ヤニナ
シュトラスブルガー,パメラ
ヴァイザー,バルバラ・マリー-ルイーゼ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2025521085A publication Critical patent/JP2025521085A/ja
Publication of JP2025521085A5 publication Critical patent/JP2025521085A5/ja
Priority to JP2026000410A priority Critical patent/JP2026062918A/ja
Application granted granted Critical
Publication of JP7801491B2 publication Critical patent/JP7801491B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024566272A 2022-05-11 2023-05-11 Vegf-aおよびil6に結合する抗体ならびに使用方法 Active JP7801491B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026000410A JP2026062918A (ja) 2022-05-11 2026-01-05 Vegf-aおよびil6に結合する抗体ならびに使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22172759.7 2022-05-11
EP22172759 2022-05-11
PCT/EP2023/062545 WO2023217933A1 (en) 2022-05-11 2023-05-11 Antibody that binds to vegf-a and il6 and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026000410A Division JP2026062918A (ja) 2022-05-11 2026-01-05 Vegf-aおよびil6に結合する抗体ならびに使用方法

Publications (3)

Publication Number Publication Date
JP2025521085A JP2025521085A (ja) 2025-07-08
JP2025521085A5 JP2025521085A5 (cg-RX-API-DMAC10.html) 2025-12-02
JP7801491B2 true JP7801491B2 (ja) 2026-01-16

Family

ID=81603574

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024566272A Active JP7801491B2 (ja) 2022-05-11 2023-05-11 Vegf-aおよびil6に結合する抗体ならびに使用方法
JP2026000410A Pending JP2026062918A (ja) 2022-05-11 2026-01-05 Vegf-aおよびil6に結合する抗体ならびに使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026000410A Pending JP2026062918A (ja) 2022-05-11 2026-01-05 Vegf-aおよびil6に結合する抗体ならびに使用方法

Country Status (16)

Country Link
US (1) US20250163139A1 (cg-RX-API-DMAC10.html)
EP (1) EP4522648A1 (cg-RX-API-DMAC10.html)
JP (2) JP7801491B2 (cg-RX-API-DMAC10.html)
KR (1) KR20250008903A (cg-RX-API-DMAC10.html)
CN (1) CN119173529A (cg-RX-API-DMAC10.html)
AR (1) AR129268A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023267952A1 (cg-RX-API-DMAC10.html)
CA (1) CA3256863A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024003373A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024015714A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240473A (cg-RX-API-DMAC10.html)
IL (1) IL316326A (cg-RX-API-DMAC10.html)
MX (1) MX2024013703A (cg-RX-API-DMAC10.html)
PE (1) PE20251283A1 (cg-RX-API-DMAC10.html)
TW (1) TW202402810A (cg-RX-API-DMAC10.html)
WO (1) WO2023217933A1 (cg-RX-API-DMAC10.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529339A (ja) 2006-03-13 2009-08-20 アブリンクス エン.ヴェー. Il−6を標的とするアミノ酸配列およびそれを含みil−6介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド
JP2014516542A (ja) 2011-05-27 2014-07-17 デュタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重標的化
JP2016503412A (ja) 2012-11-08 2016-02-04 イレブン・バイオセラピユーテイクス・インコーポレイテツド Il−6アンタゴニストおよびその使用本出願は、2012年11月8日出願の米国特許出願第61/723,972号および2013年6月6日出願の米国特許出願第61/831,699号に対する優先権を請求する。先の出願の各々の全内容はこれにより、参照により本明細書中に組み込まれる。

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ATE297452T1 (de) 1998-07-23 2005-06-15 Avebe Coop Verkoop Prod Klebemittelzusammensetzung
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
PT2600812T (pt) 2010-08-05 2021-11-09 Forsight Vision4 Inc Aparelho para tratar um olho
AU2011285637B2 (en) 2010-08-05 2014-10-30 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Fc-수용체 기재 친화성 크로마토그래피
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
US20160302965A1 (en) 2013-12-06 2016-10-20 Forsight Vision4, Inc. Implantable therapeutic devices
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
JP7674383B2 (ja) 2020-03-30 2025-05-09 エフ. ホフマン-ラ ロシュ アーゲー Vegf及びpdgf-bに結合する抗体及び使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529339A (ja) 2006-03-13 2009-08-20 アブリンクス エン.ヴェー. Il−6を標的とするアミノ酸配列およびそれを含みil−6介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド
JP2014516542A (ja) 2011-05-27 2014-07-17 デュタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重標的化
JP2016503412A (ja) 2012-11-08 2016-02-04 イレブン・バイオセラピユーテイクス・インコーポレイテツド Il−6アンタゴニストおよびその使用本出願は、2012年11月8日出願の米国特許出願第61/723,972号および2013年6月6日出願の米国特許出願第61/831,699号に対する優先権を請求する。先の出願の各々の全内容はこれにより、参照により本明細書中に組み込まれる。

Also Published As

Publication number Publication date
JP2026062918A (ja) 2026-04-10
TW202402810A (zh) 2024-01-16
PE20251283A1 (es) 2025-05-14
CA3256863A1 (en) 2023-11-16
CN119173529A (zh) 2024-12-20
CO2024015714A2 (es) 2025-04-16
WO2023217933A1 (en) 2023-11-16
IL316326A (en) 2024-12-01
CR20240473A (es) 2025-01-06
US20250163139A1 (en) 2025-05-22
EP4522648A1 (en) 2025-03-19
AU2023267952A1 (en) 2024-10-31
CL2024003373A1 (es) 2025-03-14
MX2024013703A (es) 2024-12-06
KR20250008903A (ko) 2025-01-16
AR129268A1 (es) 2024-08-07
JP2025521085A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
JP7631276B2 (ja) Vegf-a及びang2に結合する抗体及び使用方法
JP7680504B2 (ja) Vegf及びil-1ベータに結合する抗体と使用方法
KR20170082520A (ko) 항-pdgf-b 항체 및 이의 사용 방법
EP4126940A1 (en) Antibody that binds to vegf and pdgf-b and methods of use
US20250163139A1 (en) Antibody that binds to vegf-a and il6 and methods of use
RU2837708C1 (ru) Антитело, которое связывается с vegf-a и ang2, и способы применения
RU2816476C2 (ru) Антитело, которое связывается с vegf и il-1бета, и способы применения
HK40114363A (en) Antibody that binds to vegf-a and il6 and methods of use
HK40086991A (en) Antibody that binds to vegf-a and ang2 and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251120

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260105

R150 Certificate of patent or registration of utility model

Ref document number: 7801491

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150